Sustainable Financing – Are We Building Half a Bridge?

3:15 PM - 4:15 PM, Tuesday, June 4,2019 ・ 115C, Level 100
This Session will discuss financing approaches for developing and commercializing innovative products for diseases with low market incentives. Panel members will explore how funders are thinking about and cooperating to achieve a continuous support where needed as well as the pitfalls of funding only one slice of product development and commercialization. Key private and government funders will give their views on how funders and companies can ensure sustainable support for infectious disease products through the commercialization, including TB, small molecules, vaccines, and antimicrobial resistance (AMR) products.
Moderator
photo
Deputy Assistant Secretary for Preparedness and Response, Director of Biomedical Advances Research and Development Authority
U.S. Department of Health and Human Services (HHA)
Speakers
photo
Deputy Assistant Secretary for Preparedness and Response, Director of Biomedical Advances Research and Development Authority
U.S. Department of Health and Human Services (HHA)
photo
Vice President, Essential Medicines Director
PATH
photo
Managing General Partner
Frazier Healthcare Partners
photo
CEO
Matrivax
photo
Policy Lead, Drug-Resistant Infections
Wellcome Trust